Targets › LSD1
1 program from 1 company in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2028.
Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. (UniProt, O60341)
Open in Phaseline: the race on LSD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jubilant Therapeutics | JBI-802 CoREST inhibitor dual targeting LSD1 and HDAC6 | LSD1, HDAC (class I/II) | Phase 1 | Essential Thrombocythemia (ET); Lung Cancer (NSCLC) | Jun 2028 |
Essential Thrombocythemia (ET) (1) Lung Cancer (NSCLC) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.